AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Regeneron backs $75M series A for antibody upstart Infinimmune

Nathalie Wagner

Head Of Preclinical Pharmacology Galderma

Wednesday 4th November 2026

Optimizing Dosing Strategies to Enhance Efficacy & Differentiate Dermatology Therapies

11:00 am

Explain how model-informed drug development (MIDD) approaches, integrating clinical data and quantitative pharmacology methodologies, were applied to support dose selection for nemolizumab in 2 different indications
Demonstrate the role of body weight as a key intrinsic covariate influencing the PK profile of nemolizumab, and how this finding informed the implementation of a body weight–
tiered dosing strategy in Prurigo Nodularis versus a fixed dosing regimen in Atopic Dermatitis